Phase II Study of Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab as a Third-line or Later-line Therapy for Patients with Metastatic Gastric Cancer

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 7ce1dc90ad498a6827cb6a0287b9500a5c675a05
First added on: Oct 10, 2026